Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Cassiopea SpA    SKIN   IT0005108359

CASSIOPEA SPA

(SKIN)
  Report  
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Cassiopea announces 2018 Results in line with expectations

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/08/2019 | 01:05am EDT

Cassiopea announces 2018 Results in line with expectations

Lainate, Italy - 8 February 2019 - Cassiopea SpA (SIX: SKIN), a clinical-stage specialty pharmaceutical company focused on developing and commercializing innovative and differentiated medical dermatology products, today announced its results for the year ended December 31, 2018.

Key Highlights:

  • The results of the two pivotal phase III clinical trials for the topical anti-androgen Clascoterone (Winlevi® cream 1%) in acne demonstrated highly statistically significant improvements for all primary and secondary clinical end points and that the drug is generally safe and well tolerated.
  • The top line results of the planned six-month interim analysis for the phase II dose ranging study for Clascoterone (Breezula®) solution in androgenic alopecia in men demonstrated statistically significant improvement for Target Area Hair Count (TAHC) and directional improvement for Hair Growth Assessment (HGA).
  • Positive top line results of the phase II proof of concept trial for CB-06-02, a novel integrin activator for the treatment of genital warts.
  • All operations were carried out within the budgeted framework. In 2018, Cassiopea spent EUR 14,130 thousand, predominantly in the advancement of our clinical programs. At end of 2018, cash amounted to EUR 4,609 thousand, which is in line with what had originally been planned.

Financial Highlights:

  • There were no operating revenues because all products are still in development and none were licensed out.
  • R&D expenses decreased by 6,3% to EUR 12,240 thousand. The main costs were the costs of the two phase III pivotal clinical trials for Winlevi® in acne and the phase II dose ranging trial for Breezula® in alopecia.
  • SG&A expenses increased by 27,4% to EUR 1,890 thousand, primarily because of Winlevi® pre-commercial activities.
  • A net tax credit of EUR 916 thousand on the R&D costs has been recognized according to the Italian tax law.
  • Operating losses increased by 23,2% to EUR 13,214 thousand.
  • A net financial income of EUR 558 thousand resulted from foreign exchange gain given that the majority of financial assets were held in US$.
  • At year-end, cash and cash equivalents amounted to EUR 4,609 thousand. In addition to this, the Company had an undrawn credit facility of EUR 10 million granted by its largest shareholder Cosmo Pharmaceuticals N.V. that has indicated the willingness to increase this to EUR 20 million.

Diana Harbort, CEO of Cassiopea SpA, commented: "2018 was very successful year. We made substantial progress in each of our programs. We met the desired clinical endpoints for all three ongoing trials: The Phase III data for Winlevi®, the interim six-month results for the Breezula® Dose Ranging Trial and the POC results for CB-06-02. 2019 will be a year of growth and change for Cassiopea, as we submit the NDA to the FDA and invest in the pre-commercial activities for Winlevi®, advance Breezula® into Phase III for androgenetic alopecia, and begin to build the infrastructure of the Company. Cosmo has provided a EUR 10 million term loan, but completion of the clinical trials and building the sales and marketing organization in the US will require substantial funds. We thus plan to access capital with the intention to give existing shareholders - as well as new US-based investors - the opportunity to invest in our Company. We are convinced that we have one of the most innovative pipelines in the dermatology industry and view the future with great optimism."

Key Financial Figures

In EUR thousands

(with the exception of the share data in €)

2018

2017

Revenues

-

-

Other income

916

3,820

Cost of sales

Research and development costs

(12,240)

(13,061)

Selling, general and administrative costs

(1,890)

(1,484)

Operating Result

(13,214)

(10,725)

Net financial income

558

(2,931)

Loss before taxes

(12,656)

(13,656)

Net loss

(12,656)

(13,656)

Loss per share

(1.266)

(1.366)

31.12.2018

31.12.2017

Cash and cash equivalents

4,609

17,598

Other assets

11,931

10,871

Equity

14,512

26,354

Total assets

16,540

28,469

The Annual Report 2018 is available on the Company's website at:

www.cassiopea.com/investor-relations/financial-reports/yr-2019.aspx

2018 results presentation and conference call at 15:00 CET on 8 February 2019:

Diana Harbort, CEO; Luigi Moro, CSO; Alessandro Mazzetti, CMO; Chris Tanner, CFO; and Marco Lecchi, Deputy CFO, will present the 2018 results and discuss the outlook for 2019 at a conference call to be held today at 15:00 CET.

The dial-in numbers:

Switzerland / Europe:

+41 (0) 58 310 50 00

United Kingdom:

+44 (0) 207 107 0613

United States:

+1 (1) 631 570 56 13

The presentation for this call is available on the Company's website via:

www.cassiopea.com/investor-relations/presentations/yr-2019.aspx




Provider
Channel
Contact
Tensid EQS Ltd., Switzerland
www.tensid.ch


newsbox.ch
www.newsbox.ch


Provider/Channel related enquiries
marco@tensid.ch
+41 41 763 00 50
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CASSIOPEA SPA
05/08COSMO PHARMACEUTICALS : FDA Allowance of IND application for CB-03-10
AQ
04/16Cassiopea Announces Very Positive Phase II Twelve Months Results for Breezula..
TE
04/01Cosmo Full-Year Report 2018
AQ
03/26Cassiopea Announces Positive Results from Phase III Acne Open-Label Safety St..
TE
03/19Cassiopea announces results of ordinary and extraordinary shareholders meetin..
TE
02/08Cassiopea announces 2018 Results in line with expectations
TE
2018Cassiopea announces attainment of all primary and secondary endpoints and hig..
TE
2018Cassiopea enters into loan agreement with Cosmo Pharmaceuticals NV
TE
2018CASSIOPEA : Command and control system
AQ
2018Cassiopea Announces Top Line Positive Proof of Concept Phase II Results for C..
TE
More news
Financials (€)
Sales 2019 -
EBIT 2019 -18,5 M
Net income 2019 -21,2 M
Debt 2019 18,3 M
Yield 2019 -
P/E ratio 2019 -
P/E ratio 2020
EV / Sales 2019 0
EV / Sales 2020 6,95x
Capitalization 401 M
Chart CASSIOPEA SPA
Duration : Period :
Cassiopea SpA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CASSIOPEA SPA
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 70,0 €
Spread / Average Target 75%
EPS Revisions
Managers
NameTitle
Diana Harbort Chief Executive Officer & Executive Director
Jan Egbert de Vries Non-Executive Chairman
Marco Pasero Chief Operating Officer
Hans Christoph Tanner CFO, Head-Investor & Media Relations
Luigi Moro Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
CASSIOPEA SPA23.22%448
GILEAD SCIENCES7.39%85 410
VERTEX PHARMACEUTICALS4.41%44 312
REGENERON PHARMACEUTICALS-14.30%33 962
GENMAB12.37%11 081
SAREPTA THERAPEUTICS INC8.36%8 769